Zentalis Pharmaceuticals has dosed the first patient in the Phase 3 ASPENOVA trial, testing azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer. This trial compares azenosertib to standard chemotherapy and aims to confirm benefits seen in earlier Phase 2 studies, supporting full FDA approval. The ASPENOVA study enrolls about 420 patients globally and focuses on progression-free survival as the primary endpoint. Results from the ongoing Phase 2 DENALI trial, expected by the end of 2026, may lead to accelerated approval, while ASPENOVA will provide confirmatory data for full approval.
A Kinder Morgan executive recently sold 5,695 shares of the company, totaling approximately $184,000, according to a recent SEC filing. This insider sale could indicate the executive's personal financial decision but does not necessarily reflect the ...
Lotus Bakeries reported 14% revenue growth and 23% EBIT increase in the first half of the year, driven by strong demand for its Biscoff products. The company is investing aggressively with a €500 million capital expenditure plan, fully supported by h...
Qualcomm is trading at $162.68 with a 24/7 Wall St. price target of $226.08, implying nearly 39% upside in the next year. Despite a recent 14% drop and handset revenue falling 20% due to China inventory issues, the company’s automotive segment grew 6...
Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by GoDaddy following the company's disclosure of a promotional pricing strategy for dotcom domains that led to a 14% stock price drop. GoDaddy revealed that the high demand ...
Metallium Limited announced successful tests of its Flash Joule Heating (FJH) technology, which enhances recovery and concentration of critical metals like rare earths, germanium, and platinum group metals from various industrial wastes and ores. The...
